Skip to main content

Table 2 Sero-prevalences of HSV type 1 and 2 according to cancer history-NHANES 1999–2014

From: Seropositivity to herpes simplex virus type 2, but not type 1 is associated with cervical cancer: NHANES (1999–2014)

Variable Status HSV1+ number HSV1- number HSV1+ weighted percent s.e. P value
Any cancer Yes 229 93 67.17 3.12 0.04
  No 5231 2631 60.39 0.91  
Breast cancer Yes 24 8 76.16 8.44 0.11
  No 5436 2716 60.65 0.90  
Cervical cancer Yes 88 40 65.23 5.75 0.44
  No 5372 2684 60.64 0.90  
Ovarian cancer Yes 21 3 77.82 11.77 0.22
  No 5439 2721 60.68 0.90  
Uterine cancer Yes 30 4 92.24 4.51 <0.01
  No 5430 2720 60.61 0.90  
Variable Status HSV2+ number HSV2- number HSV2+ weighted percent s.e. P value
Any cancer Yes 119 203 34.26 3.51 <0.01
  No 2144 5718 24.54 0.66  
Breast cancer Yes 8 24 23.64 9.23 0.88
  No 2255 5897 25.02 0.64  
Cervical cancer Yes 56 72 40.05 5.41 <0.01
  No 2207 5849 24.74 0.65  
Ovarian cancer Yes 11 13 44.41 12.95 0.09
  No 2252 5908 24.96 0.65  
Uterine cancer Yes 15 19 57.99 11.61 <0.01
  No 2248 5902 24.89 0.65  
  1. Abbreviations: HSV1, herpes simplex virus type 1; HSV2, herpes simplex virus type 2; +, positive; −, negative; s.e., standard error; NHANES, National Health and Nutrition Examination Survey